Blue Cross Blue Shield · Arni Entresto · US health-plan appeal rights

Arni Entresto denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Arni Entresto denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for arni entresto are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS medical policy / Anthem clinical guideline — Entresto (Sacubitril/Valsartan)

The Blue Cross Blue Shield angle on Arni Entresto

## Why BCBS Denied Entresto as "Duplicate Therapy"

Entresto (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor (ARNI) approved for heart failure with reduced ejection fraction. A "duplicate therapy" denial typically occurs when BCBS's claims system detects that the patient is also receiving an ACE inhibitor (ACEi) or another angiotensin receptor blocker (ARB) — drug classes that share part of Entresto's mechanism. The insurer's automated review flags this as therapeutic duplication.

However, this denial reflects a clinical misunderstanding. Entresto is not prescribed in addition to an ACEi or ARB — it is intended to replace them. When a prescriber transitions a patient to Entresto, a washout period from the prior ACEi or ARB is required per the FDA-approved prescribing information. If a crossover claim appeared during that washout window, it can trigger a false duplicate-therapy flag.

## Why This Is Appealable

The FDA-approved label for Entresto explicitly addresses the transition from ACEi/ARB therapy and the required washout period. The appeal should demonstrate that (1) the prior ACEi or ARB was discontinued as part of the transition, (2) the prescribing clinician intended Entresto as a replacement — not an addition — and (3) the patient's heart failure management is within the FDA-labeled indication. Current ACC/AHA heart failure guidelines (consult the applicable published version) address the role of ARNI therapy; the prescriber should reference the relevant guideline organization's recommendation.

## Federal Appeal Framework

Internal appeal: File within the deadline on the denial letter. A brief prescriber cover letter clarifying the transition plan is often sufficient to resolve this denial at the internal level.
ACA §2719 external review: If the internal appeal fails, an IRO will review the clinical record. Window is approximately four months from final internal denial. Expedited review is available for urgent cardiac situations.
ERISA §503: For employer-sponsored BCBS plans, requires full-and-fair review including disclosure of the criteria applied.

## What to Gather

Transition documentation: Chart note, prescription records, or pharmacy fill history showing the date the prior ACEi or ARB was stopped.
Prescriber letter: A letter clarifying that Entresto was prescribed as a replacement, not an addition, and that any overlap in claims reflects the washout transition period.
Diagnosis and LVEF documentation: Echo or imaging report confirming the diagnosis and functional status that places the patient within Entresto's FDA-labeled indication.
FDA label reference: Cite the prescribing information's transition guidance to establish that the clinical approach was label-compliant.

## Criteria-Mapping Structure

In the appeal letter, address the duplicate-therapy flag directly: quote the relevant section of the Entresto prescribing label addressing transition from ACEi/ARB, and provide the pharmacy records or chart note showing the prior agent was discontinued. This is a strong, factually specific rebuttal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Arni Entresto

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.